Sickle cell drug voxelotor tested for brain benefits in kids – study cut short

NCT ID NCT05018728

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether voxelotor, a daily pill for sickle cell anemia, can improve blood flow and oxygen supply to the brain in children. The trial planned to enroll 22 participants aged 4 to 30 years with a severe form of sickle cell disease. However, the study was terminated early, so the results are limited and we cannot draw firm conclusions about the drug's brain benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Voxelotor (also called Oxbryta), a daily oral drug
What this could lead to
If successful, this could show that voxelotor improves brain health in children with sickle cell anemia, potentially reducing the risk of stroke or cognitive issues.
What could go wrong
The study was terminated early with only 22 participants, so we have very little data. It is unclear if the drug actually improves brain function, and it may not work for all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aflac Sickle Cell Comprehensive Clinics at Children's Healthcare of Atlanta, Scottish Rite

    Atlanta, Georgia, 30342, United States

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.